| Name | Title | Contact Details |
|---|
TouchPointCare is a Libertyville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
American Disabilities Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Microbot Medical was founded with the vision of pioneering Micro Invasive Surgery, transforming one of the biggest trends in healthcare - Minimally Invasive Surgery (estimated to be close to $20B by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. Microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. Through its unique platforms, Microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. Microbot`s ViRob platform is an Autonomous Advancing Micro Robot (AAMR), less then 1mm in diameter, which has the ability to advance (forward/backward) within cavities/lumens (such as the typical human body`s veins and arteries). The TipCat platform is a self-propelled, flexible, see & treats endoscope/catheter. It is comprised of a series of interconnected balloons that provide forward and backward motion while allowing for a working channel to be available during the procedure. In developing its platforms, the company is focusing on multi-disciplinary platform of products.
To improve the lives of those impacted by disease and disability. To provide accessible, accurate, and reliable analysis in a way that facilitates and adapts to our clients` needs to progress their clinical trials at the fastest possible pace. While our technology makes us unique, it is our people who make us special. Our teams utilize creativity, flexibility and expertise to design personalized solutions to meet our customers` goals and objectives. But what truly sets us apart is the internal motivation of our employees and the pride they take in helping customers affect the lives of those in need.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.